AstraZeneca looks to CRISPR to boost success ratesBetween 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below Share XAstraZeneca looks to CRISPR to boost success rateshttps://pharmaphorum.com/views-and-analysis/astrazeneca-crispr-boost-success-rates/